"10.1371_journal.pone.0058866","plos one","2013-03-15T00:00:00Z","Chris V Bowen; Drew DeBay; H Stephen Ewart; Pamela Gallant; Sean Gormley; T Toney Ilenchuk; Umar Iqbal; Tyler Lutes; Marzia Martina; Geoffrey Mealing; Nadine Merkley; Sandra Sperker; Maria J Moreno; Christopher Rice; Raymond T Syvitski; John M Stewart","National Research Council of Canada, Institute for Biodiagnostics (Atlantic) - Neuroimaging Research Laboratory, Halifax, Nova Scotia, Canada; National Research Council of Canada, Institute for Marine Biosciences, Halifax, Nova Scotia, Canada; Soricimed Biopharma Inc., Sackville, New Brunswick, Canada; National Research Council of Canada, Institute of Biological Sciences - Neurobiology Program, Ottawa, Ontario, Canada","Conceived and designed the experiments: CVB HSE TTI UI MM GM NM MM RTS JMS. Performed the experiments: DD HSE TL NM SS PG CR SG. Analyzed the data: CVB HSE UI MM GM NM MM RTS. Contributed reagents/materials/analysis tools: TTI TL CR JMS SG. Wrote the paper: HSE RTS NM JMS.","SG, TTI, TL, CR and JMS are employees of Soricimed Biopharma Inc. At the time of performing and interpreting the results, HSE was an employee of NRC. Novaceutics Consulting has no affiliation with Soricimed. JMS has the following patents to declare: US 7,119,168 for peptides and methods of treating cancer, issued Oct. 10, 2006; US 7,273,850 for methods of inhibiting calcium uptake by a cancer cell to reduce cell proliferation by administering all or part of the peptide and methods of treating cancer where cancer cells show increased expression of TRPV6, issued Sept. 25, 2007; and US 8,211,857 for claims directed towards a peptide consisting of SOR-C13 or SOR-C27, for cancer treatment issued July 3, 2012. JMS also declares pending patents issued in: US 13/526,045 for a continuation of US 12/866,397 (US issued patent 8,211,857) for methods on inhibiting calcium uptake by cancer cells to reduce cell proliferation and methods of treating cancer; Canada (CA 2,718,949), Europe (EU 09721272.4), Japan (JP 2011-500019), and Hong Kong (11106921.8) for PCT application to national phase directed towards peptide consisting of SOR-C13 and SOR-C27; Canada 2,544,467 for the peptide directed pharmaceutical compositions and medical treatments; US 12/824,935 for TRPV6-binding peptides comprising all or part of SOR-C27 conjugated to a biomolecule. JMS declares PCT applications in nation phase in Canada (CA 2,766,272), Europe (EU 10791109.1), Hong Kong (serial number 12110289.5), Japan (JP 2012-516450), Mexico (MX/a/2012/000086) and Brazil (PI1012676-9). This does not alter the authors' adherence to all the PLOS ONE policies on sharing data and materials, as detailed online in the guide for authors.","2013","03","Chris V Bowen","CVB",16,TRUE,9,8,7,4,TRUE,TRUE,FALSE,0,NA,FALSE
